Angitia Biopharmaceuticals

This phase 3 study tests a single injection of AGA111 given directly into the spine during lumbar fusion surgery for people with degenerative disc disease. The goal is to see if it improves bone fusion and reduces disability compared to a placebo. About 412 adults aged 18 to 80 w…

This study tests a new medicine called AGA2118 to see if it can improve bone density in postmenopausal women who have weak bones but no fractures. About 379 healthy women aged 55 to 80 with low bone mineral density will receive either the drug or a placebo for 12 months. The main…